To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

• ClinicalTrials.gov Identifier: NCT02085161
• Recruitment Status: Completed
• First Posted: March 12, 2014
• Results First Posted: January 6, 2017
• Last Update Posted: January 6, 2017
• Sponsor: Boehringer Ingelheim
• Information provided by (Responsible Party): Boehringer Ingelheim

Study Description

Brief Summary:

The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of behavioural modification in improving exercise capacity in patients with COPD

Condition or disease	Intervention/treatment	Phase
Pulmonary Disease, Chronic Obstructive	Drug: placebo to tiotropium + olodaterol; Drug: tiotropium+olodaterol; Drug: tiotropium +olodaterol; Drug: tiotropium	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 304 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single
• Primary Purpose: Treatment
• Official Title: An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)
• Study Start Date: March 2014
• Actual Primary Completion Date: August 2015
• Actual Study Completion Date: October 2015

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: placebo; patient will receive placebo once daily, 2 puffs in the morning	Drug: placebo to tiotropium + olodaterol; comparator
Experimental: tiotropium + olodaterol high dose with BM; patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning	Drug: tiotropium +olodaterol; olodaterol 5 mcg once daily fixed dose combination
Active Comparator: tiotropium; patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning	Drug: tiotropium; tiotropium 5 mcg once daily fixed dose combination
Experimental: tiotropium + olodaterol with exercise training and BM; patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning	Drug: tiotropium+olodaterol; tiotropium 5 mcg once daily

Outcome Measures

Primary Outcome Measures :

1. Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 8 Weeks [ Time Frame: Week 8 ]
   Endurance time during ESWT to symptom limitation at walking speed corresponding to 85% of predicted maximum oxygen consumption (VO2 peak) after 8 weeks of pharmacological treatment and non-pharmacological intervention. The numerical value of endurance time in seconds was transformed in log10 scale to correct for skewness and then an analysis of covariance (ANCOVA) was fitted to the log10-transformed data and the least square means (LSMean) and standard error (SE) were obtained. To present the results in a way easier for interpretation, the least square mean from the ANCOVA fitted to the log10-transformed data were transformed back taking 10 to the power of the least square estimate to obtain the geometric mean and the corresponding SE was transformed using delta method to get the corresponding SE of the geometric mean.

Secondary Outcome Measures :

1. Average Daily Walking Time Measured by the Activity Monitor in the Week Prior to Week 12 [ Time Frame: Week 12 ]
   Average daily walking time measured by the activity monitor in the week prior to Week 12.
2. Average Daily Walking Intensity Measured by the Activity Monitor in the Week Prior to 12 Weeks of Treatment [ Time Frame: Week 12 ]
   Average daily walking intensity measured by the activity monitor in the week prior to 12 weeks of treatment. The Movement Intensity (MI) is derived from the acceleration signals. Since seismic sensors measure gravitational acceleration (g) in static situations, the acceleration signal is expressed relative to g (1g = 9.81m/s2). To calculate movement intensity (MI) the gravitational acceleration in static situations was removed and the rotation vector of the three accelerometer signals was calculated. The MI gives an indication of the power of movements.
3. Perceived Difficulties as Evaluated With Functional Performance Inventory-Short Form (FPI-SF) Total Score at Week 12 [ Time Frame: Week 12 ]
   Perceived difficulties as evaluated with FPI-SF. FPI-SF self-report questionnaire has 6 domains: Body care(5 items), Household maintenance(8 items), Physical exercise(5 items), Recreation(5 items), Spiritual activities(4 items) and Social interaction(5 items) with five possible answers on each item: Do with no difficulty - 3, Do with some difficulty - 2, Do with great difficulty - 1, don't do because of health reasons - 0, and don't do because choose not to - 0. Domain scores are expressed as mean values, with at least 6 non-missing items required for the household maintenance domain and at least 3 non-missing items for the other domains. Total score is the mean across the six domains. So total and domain scores range from 0 to 3, with higher scores indicating higher levels of functional activity within and across domains. Respondents engaged in many activities with no difficulty will score high on the FPI, while those who perform few activities with much difficulty will score low.
4. Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 12 Weeks [ Time Frame: Week 12 ]
   Endurance time during ESWT to symptom limitation at walking speed corresponding to 85% of maximum oxygen consumption (VO2 peak) after 12 weeks of pharmacological treatment and non-pharmacological intervention. The numerical value of endurance time in seconds was transformed in log10 scale to correct for skewness and then the ANCOVA was fitted to the log10-transformed data and the least square means and SE were obtained. To present the results in a way easier for interpretation, the least square mean from the ANCOVA fitted to the log10-transformed data were transformed back taking 10 to the power of the least square estimate to obtain the geometric mean and the corresponding SE was transformed using delta method to get the corresponding SE of the geometric mean.
5. One Hour, Post-dose Forced Expiratory Volume in One Second (FEV1) After 8 Weeks of Treatment [ Time Frame: Week 8 ]
   One hour, Post-dose Forced Expiratory Volume in One Second (FEV1) after 8 weeks of treatment.
6. One Hour, Post-dose Forced Vital Capacity (FVC) After 8 Weeks of Treatment [ Time Frame: Week 8 ]
   One hour, Post-dose Forced Vital Capacity (FVC) after 8 weeks of treatment.
7. Resting Inspiratory Capacity (IC) Measured at 1.5 Hours Post Dose After 8 Weeks of Treatment [ Time Frame: Week 8 ]
   Resting inspiratory capacity (IC) measured at 1.5 hours post dose after 8 weeks of treatment.

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

• All patients must sign an informed consent consistent with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator forced expiratory volume in one second >=30% and <80% of predicted normal; Global Initiative for Chronic Obstructive Lung Disease grade II - III, and a post-bronchodilator Tiffeneau index <70% at Visit 1.
• Male or female patients, aged >=40 years and <=75 years.
• Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.

Exclusion criteria:

• Patients with a significant disease other than chronic obstructive pulmonary disease.
• Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis.
• Patients with a history of asthma.
• A diagnosis of thyrotoxicosis.
• A diagnosis of paroxysmal tachycardia (>100 beats per minute).
• A history of myocardial infarction within 1 year of screening visit.
• Unstable or life-threatening cardiac arrhythmia.
• Hospitalized for heart failure within the past year.
• Known active tuberculosis.
• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years.
• A history of life-threatening pulmonary obstruction and patients with chronic respiratory failure.
• A history of cystic fibrosis.
• Clinically evident bronchiectasis.
• A history of significant alcohol or drug abuse.
• Any contraindications for exercise testing.
• Patients who have undergone thoracotomy with pulmonary resection.
• Patients being treated with any oral ß-adrenergics.
• Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigators opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
• Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
• Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
• Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, benzalkonium chloride, disodium edentat, or any other component of the Respimat® inhalation solution delivery system.
• Pregnant or nursing women.
• Women of childbearing potential not using highly effective methods of birth control.
• Patients who have previously been randomized in this study or are currently participating in another study.

Contacts and Locations

Locations

United States, California

Boehringer Ingelheim Investigational Site

San Diego, California, United States

Boehringer Ingelheim Investigational Site

Torrance, California, United States

United States, Connecticut

Boehringer Ingelheim Investigational Site

Hartford, Connecticut, United States

Australia, South Australia

Boehringer Ingelheim Investigational Site

Daw Park, South Australia, Australia

Boehringer Ingelheim Investigational Site

Glen Osmond, South Australia, Australia

Austria

Boehringer Ingelheim Investigational Site

Salzburg, Austria

Belgium

Boehringer Ingelheim Investigational Site

Genk, Belgium

Boehringer Ingelheim Investigational Site

Hasselt, Belgium

Boehringer Ingelheim Investigational Site

Leuven, Belgium

Canada, Quebec

Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

Boehringer Ingelheim Investigational Site

Ste-Foy, Quebec, Canada

Canada, Saskatchewan

Boehringer Ingelheim Investigational Site

Saskatoon, Saskatchewan, Canada

Denmark

Boehringer Ingelheim Investigational Site

Kolding, Denmark

Boehringer Ingelheim Investigational Site

København NV, Denmark

Boehringer Ingelheim Investigational Site

Odense, Denmark

Germany

Boehringer Ingelheim Investigational Site

Berlin, Germany

Boehringer Ingelheim Investigational Site

Bochum, Germany

Boehringer Ingelheim Investigational Site

Frankfurt, Germany

Boehringer Ingelheim Investigational Site

Großhansdorf, Germany

Boehringer Ingelheim Investigational Site

Heidelberg, Germany

Boehringer Ingelheim Investigational Site

Leverkusen, Germany

Boehringer Ingelheim Investigational Site

Solingen, Germany

Boehringer Ingelheim Investigational Site

Teuchern, Germany

Boehringer Ingelheim Investigational Site

Tübingen, Germany

New Zealand

Boehringer Ingelheim Investigational Site

Greenlane East Auckland NZ, New Zealand

Poland

Boehringer Ingelheim Investigational Site

Gdansk, Poland

Boehringer Ingelheim Investigational Site

Lodz, Poland

Boehringer Ingelheim Investigational Site

Starachowice, Poland

Portugal

Boehringer Ingelheim Investigational Site

Coimbra, Portugal

Boehringer Ingelheim Investigational Site

Lisboa, Portugal

Boehringer Ingelheim Investigational Site

Porto, Portugal

United Kingdom

Boehringer Ingelheim Investigational Site

Leicester, United Kingdom

Boehringer Ingelheim Investigational Site

Norwich, United Kingdom

Boehringer Ingelheim Investigational Site

Sheffield, United Kingdom

Sponsors and Collaborators

Boehringer Ingelheim

Investigators

• Study Chair: Boehringer Ingelheim; Boehringer Ingelheim

More Information

Additional Information:

Related Info 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, Korducki L, Hamilton A. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016 Apr 13;6(4):e010106. doi: 10.1136/bmjopen-2015-010106.

Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, Maltais F, Troosters T, Leidy N. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation. BMJ Open. 2016 Apr 4;6(4):e010109. doi: 10.1136/bmjopen-2015-010109.

• Responsible Party: Boehringer Ingelheim
• ClinicalTrials.gov Identifier: NCT02085161
• Other Study ID Numbers: 1237.16; 2013-002671-18 ( EudraCT Number: EudraCT )
• First Posted: March 12, 2014
• Results First Posted: January 6, 2017
• Last Update Posted: January 6, 2017
• Last Verified: November 2016

Additional relevant MeSH terms:

Lung Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Lung Diseases, Obstructive; Tiotropium Bromide; Olodaterol; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Asthmatic Agents; Respiratory System Agents; Parasympatholytics; Cholinergic Antagonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action